Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib and Pemetrexed/Carboplatin in EGFR+ Metastatic NSCLC With Brain Metastases After Osimertinib Failure
NCT05477615Phase 2Terminated
- Start
- Aug 2022
- Primary completion
- Oct 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib in non-small cell lung cancer (NSCLC). Started Aug 2022; status: terminated.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05477615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477615.